ATB Stock Overview
Produces and sells medicinal products in Romania. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
My Notes
Capture your thoughts, links and company narrative
Antibiotice S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | RON 2.54 |
| 52 Week High | RON 3.44 |
| 52 Week Low | RON 1.36 |
| Beta | 0.14 |
| 1 Month Change | -7.64% |
| 3 Month Change | -18.85% |
| 1 Year Change | 78.87% |
| 3 Year Change | 326.17% |
| 5 Year Change | 396.09% |
| Change since IPO | 2,982.97% |
Recent News & Updates
Recent updates
Is Antibiotice (BVB:ATB) Using Too Much Debt?
Nov 23
Market Might Still Lack Some Conviction On Antibiotice S.A. (BVB:ATB) Even After 25% Share Price Boost
Jun 07Antibiotice S.A. (BVB:ATB) Looks Just Right With A 26% Price Jump
Jan 30We Think Antibiotice (BVB:ATB) Can Manage Its Debt With Ease
Jan 13These 4 Measures Indicate That Antibiotice (BVB:ATB) Is Using Debt Safely
Aug 16Is Antibiotice (BVB:ATB) A Risky Investment?
Jun 08These 4 Measures Indicate That Antibiotice (BVB:ATB) Is Using Debt Extensively
Mar 10Tread With Caution Around Antibiotice S.A.'s (BVB:ATB) 5.8% Dividend Yield
Feb 11Calculating The Intrinsic Value Of Antibiotice S.A. (BVB:ATB)
Jan 12Are Antibiotice's (BVB:ATB) Statutory Earnings A Good Guide To Its Underlying Profitability?
Dec 16
Is Antibiotice (BVB:ATB) Using Too Much Debt?
Nov 24Shareholder Returns
| ATB | RO Pharmaceuticals | RO Market | |
|---|---|---|---|
| 7D | -4.5% | -7.3% | -3.4% |
| 1Y | 78.9% | -3.3% | 5.2% |
Return vs Industry: ATB exceeded the RO Pharmaceuticals industry which returned -3.3% over the past year.
Return vs Market: ATB exceeded the RO Market which returned 5.2% over the past year.
Price Volatility
| ATB volatility | |
|---|---|
| ATB Average Weekly Movement | 6.6% |
| Pharmaceuticals Industry Average Movement | 5.4% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in RO Market | 12.0% |
| 10% least volatile stocks in RO Market | 2.9% |
Stable Share Price: ATB has not had significant price volatility in the past 3 months compared to the RO market.
Volatility Over Time: ATB's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1955 | 1,352 | Ioan Nani | www.antibiotice.ro |
Antibiotice S.A. produces and sells medicinal products in Romania. The company produces medicines for a range of therapeutic areas, such as cardiovascular system, alimentary tract and metabolism, musculo-skeletal system, nervous system, antiinfectives, respiratory system, dermatological, food supplements, sensory organs, genito-urinary apparatus and sexual hormones, varia, and blood and blood forming organs, as well as veterinary medicinal products. It offers its products in the form of sterile injectable powders, capsules, tablets, ointments, gels, creams, and suppositories.
Antibiotice S.A. Fundamentals Summary
| ATB fundamental statistics | |
|---|---|
| Market cap | RON 1.71b |
| Earnings (TTM) | RON 92.29m |
| Revenue (TTM) | RON 657.89m |
18.5x
P/E Ratio2.6x
P/S RatioIs ATB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ATB income statement (TTM) | |
|---|---|
| Revenue | RON 657.89m |
| Cost of Revenue | RON 242.29m |
| Gross Profit | RON 415.60m |
| Other Expenses | RON 323.30m |
| Earnings | RON 92.29m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.14 |
| Gross Margin | 63.17% |
| Net Profit Margin | 14.03% |
| Debt/Equity Ratio | 13.8% |
How did ATB perform over the long term?
See historical performance and comparisonDividends
3.3%
Current Dividend Yield60%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 01:21 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Antibiotice S.A. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Raluca Negoescu | Alpha Finance Romania |
| Vladimira Urbankova | Erste Group Bank AG |
| Roxana Dascalu | SSIF IEBA Trust SA |